Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

QUILT 3.064: PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04050709
Recruitment Status : Recruiting
First Posted : August 8, 2019
Last Update Posted : August 12, 2019
Sponsor:
Information provided by (Responsible Party):
NantKwest, Inc.

Brief Summary:
Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose in subjects with locally advanced or metastatic solid cancers.

Condition or disease Intervention/treatment Phase
Locally Advanced Solid Tumor Metastatic Cancer Solid Tumor Biological: PD-L1 t-haNK Phase 1

Detailed Description:
Phase 1 study to assess the safety, preliminary efficacy of PD-L1 t-haNK and to determine the maximal tolerated dose and designate the recommended phase 2 dose for subjects with locally advanced or metastatic solid cancers. The study will be conducted in 2 parts: part 1 will involve dose escalation and part 2 will involve expansion of the recommended phase 2 dose.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 16 participants
Allocation: Non-Randomized
Intervention Model: Sequential Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Open-Label Phase 1 Study of PD-L1 t-haNK In Subjects With Locally Advanced Or Metastatic Solid Cancers
Actual Study Start Date : July 18, 2019
Estimated Primary Completion Date : August 18, 2023
Estimated Study Completion Date : December 18, 2023

Arm Intervention/treatment
Experimental: PD-L1 t-haNK Dose Level 1
PD-L1 t-haNK will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 1 is 3 to 6.
Biological: PD-L1 t-haNK
PD-L1 t-haNK Suspension for Infusion

Experimental: PD-L1 t-hanK Dose Level 2
PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level 2 is 3 to 6.
Biological: PD-L1 t-haNK
PD-L1 t-haNK Suspension for Infusion

Experimental: PD-L1 t-haNK Dose Level Recommended phase 2 dose (RP2D)
PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into RP2D is 4.
Biological: PD-L1 t-haNK
PD-L1 t-haNK Suspension for Infusion

Experimental: PD-L1 t-haNk Dose -1a (if needed)
PD-L1 will be administered to patients with locally advanced or metastatic solid cancers. Planned number of subjects to be enrolled into Dose Level -1a is 3 to six, if needed.
Biological: PD-L1 t-haNK
PD-L1 t-haNK Suspension for Infusion




Primary Outcome Measures :
  1. MTD or HTD and RP2D. [ Time Frame: 1 year ]
    Maximum tolerated dose or highest tested dose and recommended phase 2 dose.

  2. Incidence of DLTs and treatment-emergent adverse events [ Time Frame: 1 year ]
    Incidence of DLTs and treatment-emergent adverse events (AEs) and serious AEs (SAEs), graded using the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.


Secondary Outcome Measures :
  1. Objective Response Rate (ORR) [ Time Frame: 1 year ]
    ORR in accordance with Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1 and modified RECIST guidelines for immunotherapy trials (iRECIST).

  2. Progression-free Survival (PFS) [ Time Frame: 1 year ]
    Progression-free Survival (PFS) by RECIST Version 1.1 and iRECIST.

  3. Overall Survival (OS) [ Time Frame: 1 year ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Age ≥ 18 years old.
  2. Able to understand and provide a signed informed consent that fulfills the relevant Institutional Review Board (IRB) or Independent Ethics Committee (IEC) guidelines.
  3. Have histologically confirmed unresectable, locally advanced or metastatic solid cancer regardless of tumor PD-L1 expression levels.
  4. Have received treatment with at least 1 prior line of therapy in the metastatic setting or not be a candidate for therapy of proven efficacy for their disease. Prior immune therapy and prior treatment with a checkpoint inhibitor as per FDA indication for current standard-of-care therapy is allowed.
  5. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  6. Have at least 1 measurable lesion and/or non-measurable disease evaluable in accordance with RECIST Version 1.1.
  7. Must have a recent formalin-fixed, paraffin-embedded (FFPE) tumor biopsy specimen obtained following the conclusion of the most recent anticancer treatment and be willing to release the specimen for exploratory tumor molecular profiling. If an historic specimen is not available, the subject must be willing to undergo a biopsy during the screening period, if considered safe by the Investigator. If safety concerns preclude collection of a biopsy during the screening period, a tumor biopsy specimen collected prior to the conclusion of the most recent anticancer treatment may be used.
  8. Must be willing to provide pre- and post-infusion blood samples for exploratory analyses.
  9. Ability to attend required study visits and return for adequate follow-up, as required by this protocol.
  10. Agreement to practice effective contraception for female subjects of child-bearing potential and non-sterile males. Female subjects of child-bearing potential must agree to use effective contraception while on study and for at least 5 months after the last dose of PD-L1 t-haNK for Infusion. Non-sterile male subjects must agree to use a condom while on study and for up to 5 months after the last dose of PD-L1 t-haNK for Infusion. Effective contraception includes surgical sterilization (eg, vasectomy, tubal ligation), two forms of barrier methods (eg, condom, diaphragm) used with spermicide, intrauterine devices (IUDs), oral contraceptives, and abstinence.

Exclusion Criteria:

  1. Body weight ≤ 50 kg at screening.
  2. Serious uncontrolled concomitant disease that would contraindicate the use of the investigational drug used in this study or that would put the subject at high risk for treatment- related complications.
  3. Systemic autoimmune disease (eg, lupus erythematosus, rheumatoid arthritis, Addison's disease, autoimmune disease associated with lymphoma).
  4. History of organ transplant requiring immunosuppression.
  5. History of or active inflammatory bowel disease (eg, Crohn's disease, ulcerative colitis).
  6. Inadequate organ function, evidenced by the following laboratory results:

    1. Absolute neutrophil count (ANC) < 750 cells/mm3.
    2. Platelet count < 75,000 cells/mm3.
    3. Hemoglobin < 9 g/dL.
    4. Total bilirubin greater than the upper limit of normal (ULN; unless the subject has documented Gilbert's syndrome).
    5. Aspartate aminotransferase (AST [SGOT]) or alanine aminotransferase (ALT [SGPT]) > 2.5 × ULN (> 5 × ULN in subjects with liver metastases).
    6. Alkaline phosphatase (ALP) levels > 2.5 × ULN (> 5 × ULN in subjects with liver metastases, or >10 × ULN in subjects with bone metastases).
    7. Serum creatinine > 2.0 mg/dL or 177 μmol/L.
  7. Uncontrolled hypertension (systolic > 160 mm Hg and/or diastolic > 110 mm Hg) or clinically significant (ie, active) cardiovascular disease, cerebrovascular accident/stroke, or myocardial infarction within 6 months prior to first study medication; unstable angina; congestive heart failure of New York Heart Association grade 2 or higher; or serious cardiac arrhythmia requiring medication.
  8. Dyspnea at rest due to complications of advanced malignancy or other disease requiring continuous oxygen therapy.
  9. Positive results of screening test for human immunodeficiency virus (HIV).
  10. Current chronic daily treatment (continuous for > 3 months) with systemic corticosteroids (dose equivalent to or greater than 10 mg/day methylprednisolone), excluding inhaled steroids. Short-term steroid use to prevent IV contrast allergic reaction or anaphylaxis in subjects who have known contrast allergies is allowed.
  11. Known hypersensitivity to any component of the study medication(s).
  12. Participation in an investigational drug study or history of receiving any investigational treatment within 14 days prior to dosing for this study, except for testosterone-lowering therapy in men with prostate cancer.
  13. Assessed by the Investigator to be unable or unwilling to comply with the requirements of the protocol.
  14. Concurrent participation in any interventional clinical trial.
  15. Pregnant and nursing women. A negative serum pregnancy test during screening and a negative pregnancy test within 72 hours prior to the first dose must be documented before PD-L1 t-haNK for Infusion is administered to a female subject of child-bearing potential.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04050709


Contacts
Layout table for location contacts
Contact: Kristin Regan, MS 310-882-0804 kristin.regan@immunitybio.com

Locations
Layout table for location information
United States, California
Chan Soon-Shiong Institute for Medicine Recruiting
El Segundo, California, United States, 90245
Contact: Lila Castillo    213-266-5605    Adelaida.Castillo@cssifm.org   
Contact: Jessica Daly, CCRP    310-486-8668    Jessica.Daly@cssifm.org   
Principal Investigator: Tara Seery, MD         
Sponsors and Collaborators
NantKwest, Inc.

Layout table for additonal information
Responsible Party: NantKwest, Inc.
ClinicalTrials.gov Identifier: NCT04050709     History of Changes
Other Study ID Numbers: QUILT 3.064
First Posted: August 8, 2019    Key Record Dates
Last Update Posted: August 12, 2019
Last Verified: August 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasm Metastasis
Neoplasms
Neoplastic Processes
Pathologic Processes